Navigation Links
ValueOptions(R) Supports New Hospital-Based Performance Measures to Help Patients Get the Best Treatment for Inpatient and Outpatient Services
Date:5/8/2009

NORFOLK, Va., May 8 /PRNewswire/ -- ValueOptions(R), Inc., the nation's largest independent behavioral health and wellness company, announces its support for the use of The Joint Commission's Hospital-Based Inpatient Psychiatric Services (HBIPS) performance measures. The basis for the recently completed pilot program was to establish a set of core performance measures to help patients receive the most appropriate and medically necessary treatment for psychiatric inpatient services and for services upon discharge. Following The Joint Commission's successful pilot testing, these performance measures are now available for widespread use in hospitals.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090106/PH55551LOGO )

There are seven HBIPS performance measures in place for hospitals which are accredited by The Joint Commission:

  • Admission screening for violence risk, substance use, psychological trauma history and patient strengths
  • Hours of physical restraint use
  • Hours of seclusion use
  • Patients discharged on multiple antipsychotic medications
  • Patients discharged on multiple antipsychotic medications with appropriate justification
  • Post discharge continuing care plan created
  • Post discharge continuing care plan transmitted to next level of care provider upon discharge

"Coordination between Inpatient and Outpatient providers in these areas will help to ensure positive outcomes for members and their families," said Renee Abdou-Malta, vice president of National Network Services for ValueOptions(R). "We very much encourage our Joint Commission-accredited providers to work together in this manner."

"Thorough assessments which lead to individualized treatment plans as well as discharge coordination are areas that ValueOptions(R) advocates," said Hal Levine, D.O., chief medical officer for ValueOptions(R). "We routinely encourage hospitals to minimize their use of seclusion, restraint and polypharmacy. The Joint Commission's measures will help all parties involved to provide optimal services when treating members."

More information regarding The Joint Commission's HBIPS performance measures can be found on The Joint Commission's Web site.

About ValueOptions(R), Inc.

ValueOptions(R), Inc., the nation's largest independent behavioral health and wellness company, provides services to more than 23 million individuals through a variety of contracts with state and county agencies and, additionally, with health plans and employers. ValueOptions(R) is a national behavioral health and wellness company that specializes in management for all behavioral health issues and promotes health and wellness through innovative programs. ValueOptions(R) mission is to improve the health and wellness for the people it serves.

www.ValueOptions.com


'/>"/>
SOURCE ValueOptions, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. First Human Study to Show Sun Chlorella A Supports Heart Health
2. Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
3. New Study Confirms That the Supports Intensity Scale Assessment is Effective in Measuring the Support Needs of People With Intellectual Disability and Making Funding Decisions
4. Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium
5. APTA Supports Surgeon Generals Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism
6. Analysis of Earlier European Stroke Trial Supports Treatment Regimen for Viprinex(TM) in Current International Phase 3 Clinical Trials
7. DSMB Again Supports Continuation of Alimera Sciences Phase 3 Clinical Trial of Iluvien(TM) for the Treatment of DME
8. New Data Presented at WCTRIMS* Supports the Importance of Early and Sustained Treatment with Betaseron(R)
9. NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
10. Journal of Antimicrobial Chemotherapy Paper Supports Additional Role for Cethromycin as Potential Treatment for Infections Caused by Community- Associated Methicillin Resistant Staphylococcus Aureus (CA-MRSA)
11. Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... 2016 , First quarter 2016 ... of $964 million , First quarter reported ... , Company revises 2016 financial guidance; now ... billion and 2016 adjusted diluted non-GAAP earnings per share to ... provides updates regarding Generics business and manufacturing facility restructuring ...
(Date:5/5/2016)... 2016 Research ... the  "Europe Thrombocythemia Market and Competitive ... their offering.       (Logo: ... latest research Europe Thrombocythemia Market and ... comprehensive insights into Thrombocythemia pipeline products, ...
(Date:5/4/2016)... 4, 2016 According to a ... Computer Interface Market - Global Industry Analysis, Size, Share, ... computer interface (BCI) market  is expected to reach a ... estimated to expand at a CAGR of 14.9 % ... A BCI device provides collaboration between the brain ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... 05, 2016 , ... A recent survey by the Midwest Business Group ... to understand and use the free preventive care benefits available to them as part ... of large, self-insured public and private employers, MBGH found that only 10% of large ...
(Date:5/5/2016)... , ... May 05, 2016 , ... ... provide focused resources for veterinary professionals across the United States. The whole food ... lives of their patients and giving dog, cat and horse owners’ peace of ...
(Date:5/5/2016)... ... 05, 2016 , ... The 2016 Nike Soccer Camp will be directed by ... coaching staff. Together they bring their winning Vandals coaching philosophy to young athletes. Programs ... 5-13, and high school players. Session dates are as follows: , Youth Day Camp ...
(Date:5/5/2016)... MA (PRWEB) , ... May 05, 2016 , ... Chronic ... becomes a constant presence, it can weaken the immune system and increase inflammation, both ... B. Bhatt, director of the adult congenital heart disease program at Harvard-affiliated Massachusetts General ...
(Date:5/5/2016)... ... ... With May flowers, summer is just around the corner. Summer means a lot of different ... the ability to play all day and night. Parents often lament the coming of summer ... themselves. Summer also means trips to the beach, backyard cookouts, fireworks on the Fourth of ...
Breaking Medicine News(10 mins):